[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338364-105":59,"doc-detail-338364-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","tight-junctions-and-cancer-targeting-claudin-1-and-claudin-4-in-thyroid-pathologies","Tight Junctions and Cancer - Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies","","Purpose: Claudins are tight junction proteins implicated in epithelial-mesenchymal transition and cancer progression. This study characterizes claudin-1 and claudin-4 expression patterns in thyroid pathologies, links them to thyroid cancer pathogenesis, and evaluates therapeutic relevance of targeting claudins. Methods: A cohort of 162 thyroid cores from patients with thyroid adenoma, goiter, and papillary, medullary, and anaplastic thyroid cancers was analyzed by immunohistochemistry. Results: Goiter showed negative claudin-1 and mostly positive claudin-4; papillary thyroid cancer and adenoma showed claudin-1 positivity, with claudin-4 also positive in papillary cancers, goiters, and adenomas. TCGA data supported overexpression in papillary thyroid cancer. Higher claudin-1 associated with worse 5-year overall survival and remained prognostic in multivariate analysis. Conclusions: Claudin staining patterns were pathology-specific across histologies; loss of claudin-1 and claudin-4 marked more aggressive cancers. Clinical translation requires further trials.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tight-junctions-and-cancer-targeting-claudin-1-and-claudin-4-in-thyroid-pathologies/338364/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tight-junctions-and-cancer-targeting-claudin-1-and-claudin-4-in-thyroid-pathologies/338364.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the study’s purpose regarding claudin proteins in thyroid disease?","Question",{"text":113,"@type":114},"To investigate claudin-1 and claudin-4 expression patterns across thyroid pathologies, relate them to thyroid cancer pathogenesis, and assess therapeutic potential of targeting claudins.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were claudin-1 and claudin-4 expression levels measured in the study?",{"text":118,"@type":114},"Thyroid tissue samples were stained for claudin-1 and claudin-4, and immunohistochemistry (IHC) analysis was performed.",{"name":120,"@type":111,"acceptedAnswer":121},"What prognostic relationship did high claudin-1 expression show in papillary thyroid cancer?",{"text":122,"@type":114},"Patients with high claudin-1 expression had significantly lower 5-year overall survival, and multivariate analysis identified high claudin-1 as an independent prognostic factor for poor outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338364,1790102622,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","pharmaceuticals  \nArticle  \nTight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies  \nJ˛edrzej Borowczak 1, Dariusz Łaszczych 2, Katarzyna Olejnik 3, Jakub Michalski 3, Anna Gutowska 2, Monika Kula 3, Anita Bator 2, Marta Sekielska-Domanowska 4, Roman Makarewicz 5, Andrzej Marszałek 6,Łukasz Szylberg 2,3,4 and Magdalena Bodnar 3,4, *  \nCitation: Borowczak, J.; Łaszczych, D.; Olejnik, K.; Michalski, J.; Gutowska, A.; Kula, M.; Bator, A.;  \nSekielska-Domanowska, M.;  \nMakarewicz, R.; Marszałek, A.; et al. Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies. Pharmaceuticals 2024, 17, 1304. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ph17101304  \nAcademic Editor: Olaf-Georg Issinger  \nReceived: 29 July 2024  \nRevised: 22 September 2024  \nAccepted: 25 September 2024  \nPublished: 30 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Clinical Oncology, Oncology Centre Prof. Franciszek Łukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland; [jedrzej.borowczak@gmail.com](jedrzej.borowczak@gmail.com)  \n2 Department of Tumor Pathology and Pathomorphology, Oncology Centre Prof. Franciszek Łukaszczyk Memorial Hospital, 85-796 Bydgoszcz, Poland; [laszczychdariusz@gmail.com](laszczychdariusz@gmail.com) (D.Ł.); [l.szylberg@cm.umk.pl](l.szylberg@cm.umk.pl) (Ł.S.)  \n3 Chair of Pathology, Dr Jan Biziel University Hospital No. 2, 85-168 Bydgoszcz, Poland  \n4 Department of Obstetrics, Gynaecology and Oncology, Collegium Medicum, Nicolaus Copernicus University, 85-168 Bydgoszcz, Poland  \n5 Department of Oncology and Brachytherapy, Collegium Medicum, Nicolaus Copernicus University, 85-796 Bydgoszcz, Poland  \n6 Chair of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences and Greater Poland Cancer Center, 61-866 Poznan, Poland  \n* [Correspondence: magdalena1bodnar@gmail.com](Correspondence: magdalena1bodnar@gmail.com)  \nAbstract: Purpose: Claudins are tight junction proteins partaking in epithelial-mesenchymal transition and cancer progression. In this study, we investigated the expression patterns of claudin-1 and claudin-4 in thyroid pathologies, discussed their links with the pathogenesis of thyroid cancers, and reviewed the therapeutic potential of targeting claudins in cancers. Methods: The research group 162 cores of thyroid samples from patients (70 female and 11 male) diagnosed with thyroid adenoma, goiter, papillary, medullary, and anaplastic thyroid cancers. All samples were stained for the expression of claudin-1 and claudin-4, and the analysis of IHC was performed. Results: Goiter samples showed negative claudin-1 and mostly positive expression of claudin-4 . Papillary thyroid cancer and thyroid adenoma showed positive expression of claudin-1, while claudin-4 was positive in papillary thyroid cancers, goiters, and adenomas. In The Cancer Genome Atlas cohort, claudin-1 and claudin-4 were overexpressed in papillary thyroid cancer compared to normal thyroid tissues. Patients with high claudin-1 expression had significantly lower 5-year overall survival than patients with low claudin-1 levels (86.75% vs. 98.65, respectively) . In multivariate analysis, high claudin-1 expression (HR 7.91, CI 95% 1.79–35, p = 0.006) and advanced clinical stage remained statistically significant prognostic factors of poor prognosis in papillary thyroid cancer. Conclusions: The pattern of claudin-1 staining was pathology-specific and changed between cancers of different histology. This phenomenon may be associated with the different pathogenesis of thyroid cancersand early metastasis. The loss of claudin-1 an","cbCailBgLmpgGiSk","https://ap.wps.com/l/cbCailBgLmpgGiSk","pdf",8897238,23,"English","# Abstract\n# Introduction\n## Tight junctions and epithelial integrity\n## EMT and carcinogenesis\n## Claudins and tight junction biology\n# Methods\n# Results\n# Discussion\n# Conclusions","[{\"question\":\"What is the study’s purpose regarding claudin proteins in thyroid disease?\",\"answer\":\"To investigate claudin-1 and claudin-4 expression patterns across thyroid pathologies, relate them to thyroid cancer pathogenesis, and assess therapeutic potential of targeting claudins.\"},{\"question\":\"How were claudin-1 and claudin-4 expression levels measured in the study?\",\"answer\":\"Thyroid tissue samples were stained for claudin-1 and claudin-4, and immunohistochemistry (IHC) analysis was performed.\"},{\"question\":\"What prognostic relationship did high claudin-1 expression show in papillary thyroid cancer?\",\"answer\":\"Patients with high claudin-1 expression had significantly lower 5-year overall survival, and multivariate analysis identified high claudin-1 as an independent prognostic factor for poor outcomes.\"}]","Tight Junctions and Cancer - Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies | PDF",1790023259,58]